An observational study in Metastatic Breast Carcinoma, sponsored by Institut de Cancérologie de Lorraine. Completed at 1 site in France. Open to female participants aged 50 Years to 70 Years. Per ClinicalTrials.gov, last updated 2018-08-08.
Sponsored by Institut de Cancérologie de Lorraine · Observational
Among 20 studies in Breast Neoplasms by Institut de Cancérologie de Lorraine — 1 open to participants now, 2 under way, none of them phase 3. Breast Neoplasms · Institut de Cancérologie de Lorraine.
Among the 20 studies in Breast Neoplasms by Institut de Cancérologie de Lorraine, this one is one of 2 that started in 2018, is one of 6 observational ones, and was the 13th registered.
14,825 studies on the registry are indexed under Breast Neoplasms; 3,319 are open to participants now.
Browse Breast Neoplasms studies →1 of the 20 studies in Breast Neoplasms by Institut de Cancérologie de Lorraine is open now, in 1 country. Recruiting first, the newest first:
Institut de Cancérologie de Lorraine · Sites in France
By country, each count listing its studies:
Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.
This study: 50 Years to 70 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 2 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 30 is below the median of 184 across 3,235 observational studies indexed under Breast Neoplasms.
Median enrollment 88 across the 14 interventional studies, 74 across the 6 observational. Of the 17 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Institut de Cancérologie de Lorraine is the lead sponsor of 62 studies on the registry; 4 are open to participants now.
1 of the studies in Breast Neoplasms by Institut de Cancérologie de Lorraine that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06552091Institut de Cancérologie de LorraineGuided Digital Self-Hypnosis Solution for Managing Hot Flashes in Patients Undergoing Adjuvant Hormone Therapy | 2027-09-20 |
Among the 20 studies in Breast Neoplasms by Institut de Cancérologie de Lorraine, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Sexual health is one of the relevant parameters for assesing the quality of life.
Improvement sexual and emotional function improves quality of life scores and depression or anxiety in curative phase.
The purpose of the study is to assess the quality of sexual life of postmenopausal women with metastatic breast cancer in couples and to establish links with overall quality of life and the quality of the relationship.
We use a quantitative methodology to assess quality of female sexual life, quality of life and quality o relationship with validated scientific questionnaires.
The sexual and emotional intimacy will be explored by semi structured interview, not mandatory for patients.
The study will be offered to women aged 50 to 70, with metastatic breast carcinoma and living in a couple and followed at the Lorraine Institute of Oncology.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
* Brief Index of Sexual Functioning for Women questionnaire * Quality of life questionnaire (EORTC QLQ-BR23) * Partnership questionnaire (partnerschaftsfragebogen; PFB) * Short interview about their sexual intimacy
Quality of sexual life of postmenopausal women with metastatic breast carcinoma living in couples
Quality of sexual life will assessed by BISF-W (Brief index of sexual functioning for women) questionnaire
Time frame: 1 day
Quality of life
Quality of life will assessed by quality of life breast cancer module questionnaire (QLQ-BR23) (Hinz et al, 2014)
Time frame: 1 day
Quality of Relationship of the couple
Quality of Relationship of the couple will assessed by partnership questionnaire (PFB). 30 items making up a global scale measuring the Quality of relationship (PFB).Quality of relationship (PFB) score can be obtained with the following equation: PFB = (30 - Quarreling) + Tenderness + Togetherness/communication ( Rossier et al, 2006).
Time frame: 1 day
Sexual and emotional intimacy
Patients will be interviewed by open-ended questions face to face concerning their Sexual and emotional intimacy.
Time frame: 1 day
Ran from Mar 2018 to primary completion in Apr 2018, 0 months.
Of 1,191 non-industry observational studies under Breast Neoplasms, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 139. This study's 0 months is below that.
Counting every sponsor, half of 1,380 studies reached it within 55 months; a quarter within 25 and three quarters within 126.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Institut de Cancérologie de Lorraine